 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Thursday
Switch From Oral Dopamine Agonist to Patch Therapy Appears Simple, Well Tolerated: Presented at ANA
A switch from an oral dopamine agonist to the experimental transdermal agent rotigotine can be accomplished overnight in patients with Parkinson's disease, researchers said here at the American Neurological Association (ANA) 131st Annual Meeting.
"Of 119 subjects enrolled in this trial, 116 patients were successfully switched to the rotigotine patch therapy," said Katherine Widnell, MD, attending neurologist and movement disorders specialist, Aurora Sinai Medical Center, Milwaukee, Wisconsin.
Aurora Sinai Medical Center cares for 5,000 patients with Parkinson's disease and other movement disorders each year, he said.
"In this trial, an overnight switch from ropinirole, pramipexole or cabergoline to rotigotine was safe and well tolerated, without exacerbating Parkinson's disease symptoms, and resulted in an overall improvement in mean Unified Parkinson's Disease Rating Scale (UPDRS) score," said Dr. Widnell, who presented the international team's work in a poster on October 10th.
Ropinirole and pramipexole are commonly used in the treatment of Parkinson's disease in the United States; cabergoline is available only in Europe, Dr. Widnell said....
A switch from an oral dopamine agonist to the experimental transdermal agent rotigotine can be accomplished overnight in patients with Parkinson's disease, researchers said here at the American Neurological Association (ANA) 131st Annual Meeting.
"Of 119 subjects enrolled in this trial, 116 patients were successfully switched to the rotigotine patch therapy," said Katherine Widnell, MD, attending neurologist and movement disorders specialist, Aurora Sinai Medical Center, Milwaukee, Wisconsin.
Aurora Sinai Medical Center cares for 5,000 patients with Parkinson's disease and other movement disorders each year, he said.
"In this trial, an overnight switch from ropinirole, pramipexole or cabergoline to rotigotine was safe and well tolerated, without exacerbating Parkinson's disease symptoms, and resulted in an overall improvement in mean Unified Parkinson's Disease Rating Scale (UPDRS) score," said Dr. Widnell, who presented the international team's work in a poster on October 10th.
Ropinirole and pramipexole are commonly used in the treatment of Parkinson's disease in the United States; cabergoline is available only in Europe, Dr. Widnell said....